■越来越多的科学证据表明,基于亚马逊植物的迷幻药“ayahuasca”对抑郁症和焦虑症等神经精神疾病具有治疗作用。然而,将植物学ayahuasca纳入生物医学研究和临床治疗环境时存在一定的挑战。受ayahuasca启发的配方,包含特定和标准化的活性成分,是一种潜在的补救措施。
■我们研究了含有可逆单胺氧化酶抑制剂harmine(含有100mgMAO-I的口腔分散片)和N,N-二甲基色胺(鼻内增量剂量高达100mgDMT),与其他两个条件相比,即单独使用harmine和安慰剂,在31名健康男性受试者的交叉RCT中。
■DMT+harmine,但不仅仅是Harmine,用5D-ASC评定量表[全球评分:F(2,60)=80.21,p<0.001]和急性经验抽样项目随时间评估的迷幻经验,以心理洞察力为特征[PIQ,F(2,58.5)=28.514,p<0.001],情感突破[EBI,F(2,60)=26.509,p<0.001],挑战性经验问卷[CEQ,F(2,60)=12.84,p<0.001]。参与者将个人和精神意义归因于经验(GSR),并在1个月和4个月的随访中主要具有积极的持续效应(PEQ)。急性药物作用与持续作用呈正相关。我们发现人格特征没有变化,心理灵活性,或总体福祉,并且没有报告精神病理学(SCL-90-R)的增加。
■我们的结果表明,标准化DMT+harmine制剂诱导的经验诱导了现象学上丰富的迷幻体验,表现出良好的心理安全性和耐受性,耐受性良好,并诱导有益的心理过程,可能支持心理治疗。需要进一步的研究来调查患者的心理治疗潜力。
UNASSIGNED: There is growing scientific evidence for the therapeutic benefits of the Amazonian plant-based psychedelic \"
ayahuasca\" for neuropsychiatric disorders such as depression and anxiety. However, there are certain challenges when incorporating botanical
ayahuasca into biomedical research and clinical therapy environments. Formulations inspired by
ayahuasca, which contain specific and standardized active components, are a potential remedy.
UNASSIGNED: We investigated subjective acute and persisting effects of a novel formulation containing the reversible monoamine oxidase inhibitor harmine (orodispersible tablet containing 100 mg MAO-I) and N,N-dimethyltryptamine (incremental intranasal dosing of up to 100 mg DMT), compared with two other conditions, namely harmine alone and placebo, in a crossover RCT in 31 healthy male subjects.
UNASSIGNED: DMT + harmine, but not harmine alone, induced a psychedelic experience assessed with the 5D-ASC rating scale [global score: F(2,60) = 80.21, p < 0.001] and acute experience sampling items over time, characterized by psychological insights [PIQ, F(2,58.5) = 28.514, p < 0.001], emotional breakthroughs [EBI, F(2,60) = 26.509, p < 0.001], and low scores on the challenging experience questionnaire [CEQ, F(2,60) = 12.84, p < 0.001]. Participants attributed personal and spiritual significance to the experience (GSR) with mainly positive persisting effects (PEQ) at 1- and 4-months follow-up. Acute drug effects correlated positively with persisting effects. We found no changes in trait measures of personality, psychological flexibility, or general well-being, and no increases in psychopathology (SCL-90-R) were reported.
UNASSIGNED: Our results suggest that the experience induced by the standardized DMT + harmine formulation induces a phenomenologically rich psychedelic experience, demonstrates good psychological safety and tolerability, is well tolerated, and induces beneficial psychological processes that could possibly support psychotherapy. Further studies are required to investigate the psychotherapeutic potential in patients.